Oncotarget

Research Papers:

A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer

Juan Zhou, Yang Yu, Yunfeng Pei, Chunping Cao, Chen Ding, Duping Wang, Li Sun and Guoping Niu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:65469-65480. https://doi.org/10.18632/oncotarget.18971

Metrics: PDF 1494 views  |   HTML 2489 views  |   ?  


Abstract

Juan Zhou1,*, Yang Yu2,*, Yunfeng Pei1, Chunping Cao1, Chen Ding1, Duping Wang1, Li Sun1 and Guoping Niu1

1Department of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People’s Republic of China

2Department of Medical Oncology, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Guoping Niu, email: [email protected]

Keywords: SPC24, lung cancer, prognostic biomarker, tumorigenesis, metastasis

Received: October 11, 2016     Accepted: June 16, 2017     Published: July 04, 2017

ABSTRACT

Results: SPC24 is over-expressed in clinical lung adenocarcinoma samples, and high level of SPC24 is associated with advanced stages of lung tumors. Knocking down SPC24 repressed cell growth and promoted apoptosis. SPC24 deficiency reduced cancer cell migration as well. E-cadherin, one of the epithelial-mesenchymal transition markers, was up-regulated in the knockdown cells, along with down-regulation of N-cadherin and Vimentin. Oncomine expression analyses further confirmed that high level of SPC24 is associated with tumors from smokers, recurrent patients, or patients with shorter survivals.

Purpose and methods: To reveal the role of SPC24, an important component of kinetochore, in the tumorigenesis of lung cancer, we performed Oncomine and immunohistochemistry (IHC) analyses for SPC24 in human lung adenocarcinoma tumors. We knocked down SPC24 in two non-small cell lung cancer (NSCLC) cell lines, PC9 and A549, by siRNA and evaluated cell proliferation, apoptosis, and migration in the SPC24-deficient cells. Using a mouse xenograft model, we compared in vivo tumor growth of the knockdown and control cells. We further performed multiple Oncomine expression analyses for SPC24 in various lung cancer datasets with important clinical characteristics and risk factors, including survival, recurrence, and smoking status.

Conclusions: SPC24 is a novel oncogene of lung cancer, and can serve as a promising prognostic biomarker to differentiate lung tumors that have various clinicopathological characteristics. The findings of the current study will benefit the diagnosis, management, and targeted therapy of lung cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18971